Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RAP1GDS1
REST API REST API
Homo sapiens
RAP1GDS1 is differentially expressed in 323 experiments: 157 organism parts: liver, amygdala, ... (155 more);, 219 disease states: normal, acute lymphoblastic leukemia, ... (217 more);, 111 cell types 419 cell lines 36 compound treatments and 79 other conditions.
Synonyms SmgGDS
Orthologs Rap1gds1 (Mus musculus)   Q2KIA8_BOVIN (Bos taurus)   RAP1GDS1 (Danio rerio)   Rap1gds1 (Rattus norvegicus)   RAP1GDS1 (Gallus gallus)   vimar (Drosophila melanogaster)   rap1gds1 (Xenopus laevis)   RAP1GDS1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, vacuolar proton-transporting V-type ATPase, V1 domain, biological_process, proton-transporting ATPase activity, rotational mechanism, GTPase activator activity, cellular_component, binding, ATP hydrolysis coupled proton transport, positive regulation of GTPase activity
InterPro Term Armadillo, ATPase_V1-cplx_hsu
UniProt Accession P52306, Q499L7, D6RE95, D6RC12, D6RC85, D6RB97, D6RBC6, D6RHZ7, D6RHH8, D6RF90, D6REZ0, B7Z4M5, E9PH06
Search EB-eye ENSG00000138698
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
Jurkat
3
E-GEOD-1880, E-MTAB-62, E-MEXP-2197
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
GM15510
2
E-GEOD-22639, E-GEOD-19466
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-TABM-420, E-GEOD-14990
MOLT4
2
E-MTAB-37, E-MTAB-62
413 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (50 experiments)

Factor Value U/D Experiments
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
white blood cell
1
E-GEOD-2006
ADC
1
1
E-GEOD-19188
plasmablast
1
E-MEXP-2360
double positive thymocyte
1
E-GEOD-1460
105 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-GEOD-16363, ... (68 experiments)

Factor Value U/D Experiments
uterine fibroid
3
E-GEOD-2724, E-GEOD-7307, E-MTAB-62
control
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121
Classic-KS, HIV-, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1004
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
213 more value(s).


Compound treatment

studied in E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (25 experiments)

Factor Value U/D Experiments
control
2
E-GEOD-3284, E-GEOD-4006
dimethyl sulfoxide
2
E-GEOD-5824, E-GEOD-6932
lipopolysaccharide
1
2
E-MEXP-1958, E-TABM-868, E-GEOD-3720
eicosapentaenoic acid
1
E-MEXP-1389
interleukin-26 (Homo sapiens)
1
E-GEOD-7216
platelet-derived growth factor
1
E-GEOD-1923
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-GEOD-22148, ... (11 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-2152, E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (15 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, E-TABM-440, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-MEXP-1648, ... (36 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-6434, ... (8 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-6532, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.421 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM